- Home
- SVRE vs OGEN Comparison
SVRE vs OGEN Comparison
Compare SVRE & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- OGEN
- Stock Information
- Founded
- SVRE 2014
- OGEN 1996
- Country
- SVRE Israel
- OGEN United States
- Employees
- SVRE N/A
- OGEN N/A
- Industry
- SVRE
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SVRE
- OGEN Health Care
- Exchange
- SVRE Nasdaq
- OGEN Nasdaq
- Market Cap
- SVRE 4.1M
- OGEN 3.9M
- IPO Year
- SVRE 2022
- OGEN N/A
- Fundamental
- Price
- SVRE $4.11
- OGEN $0.29
- Analyst Decision
- SVRE
- OGEN
- Analyst Count
- SVRE 0
- OGEN 0
- Target Price
- SVRE N/A
- OGEN N/A
- AVG Volume (30 Days)
- SVRE 69.5K
- OGEN 14.3M
- Earning Date
- SVRE 03-24-2025
- OGEN 03-28-2025
- Dividend Yield
- SVRE N/A
- OGEN N/A
- EPS Growth
- SVRE N/A
- OGEN N/A
- EPS
- SVRE N/A
- OGEN N/A
- Revenue
- SVRE $458,952.00
- OGEN N/A
- Revenue This Year
- SVRE N/A
- OGEN N/A
- Revenue Next Year
- SVRE $422.52
- OGEN N/A
- P/E Ratio
- SVRE N/A
- OGEN N/A
- Revenue Growth
- SVRE N/A
- OGEN N/A
- 52 Week Low
- SVRE $3.84
- OGEN $0.25
- 52 Week High
- SVRE $359.95
- OGEN $3.84
- Technical
- Relative Strength Index (RSI)
- SVRE 26.43
- OGEN 46.16
- Support Level
- SVRE $5.07
- OGEN $0.28
- Resistance Level
- SVRE $7.33
- OGEN $0.31
- Average True Range (ATR)
- SVRE 1.11
- OGEN 0.05
- MACD
- SVRE 0.02
- OGEN 0.00
- Stochastic Oscillator
- SVRE 5.81
- OGEN 9.39
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.